HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 04-25-2016, 03:14 PM   #1
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,778
Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall surviv

survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer.



Breast Cancer Res Treat. 2016 Apr 23. [Epub ahead of print]
Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer.
Gallagher CM1, More K2, Kamath T3, Masaquel A3, Guerin A4, Ionescu-Ittu R4, Gauthier-Loiselle M4, Nitulescu R4, Sicignano N5,6, Butts E6, Wu EQ7, Barnett B3.
Author information

1Washington Cancer Institute, MedStar Washington Hospital Center, 110 Irving Street, NW, Room C-2149, Washington, DC, 20010-2975, USA. Christopher.Gallagher@medstar.net.
2Virginia Oncology Associates, Virginia Beach, VA, USA.
3Genentech, Inc., South San Francisco, CA, USA.
4Analysis Group, Inc., Montreal, QC, Canada.
5Health ResearchTx LLC, Trevose, VA, USA.
6Navy and Marine Corps Public Health Center, Portsmouth, VA, USA.
7Analysis Group, Inc., Boston, MA, USA.
Abstract
Trastuzumab reduces the risk of relapse in women with HER2-positive non-metastatic breast cancer, but little information exists on the timing of trastuzumab initiation. The study investigated the impact of delaying the initiation of adjuvant trastuzumab therapy for >6 months after the breast cancer diagnosis on time to relapse, overall survival (OS), and relapse-free survival (RFS) among patients with non-metastatic breast cancer. Adult women with non-metastatic breast cancer who initiated trastuzumab adjuvant therapy without receiving any neoadjuvant therapy were selected from the US Department of Defense health claims database from 01/2003 to 12/2012. Two study cohorts were defined based on the time from breast cancer diagnosis to trastuzumab initiation: >6 months and ≤6 months. The impact of delaying trastuzumab initiation on time to relapse, OS, and RFS was estimated using Cox regression models adjusted for potential confounders. Of 2749 women in the study sample, 79.9 % initiated adjuvant trastuzumab within ≤6 months of diagnosis and 20.1 % initiated adjuvant trastuzumab >6 months after diagnosis. After adjusting for confounders, patients who initiated trastuzumab >6 months after the breast cancer diagnosis had a higher risk of relapse, death, or relapse/death than those who initiated trastuzumab within ≤6 months of diagnosis (hazard ratios [95 % CIs]: 1.51 [1.22-1.87], 1.54 [1.12-2.12], and 1.43 [1.16-1.75]; respectively). The results of this population-based study suggest that delays of >6 months in the initiation of trastuzumab among HER2-positive non-metastatic breast cancer patients are associated with a higher risk of relapse and shorter OS and RFS.

KEYWORDS:
HER2-positive non-metastatic breast cancer; Overall survival; Relapse-free survival; Trastuzumab
PMID: 27107569 [PubMed - as supplied by publisher]
Lani is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 03:14 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter